NME2 and nonpapillary renal cell carcinoma: Additionally, immunohistochemistry clarified differences in NME2 expression between normal and tumor tissues, providing strong experimental evidence for NME2 as a therapeutic target in ccRCC.Although we did not perform direct senescence assays, the observed reduction in cell proliferation upon NME2 knockdown (a hallmark of senescence) is consistent with the predicted pro-senescence role of this gene within our model.